<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Bortezomib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Bortezomib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Bortezomib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Bortezomib</b>, sold under the brand name <b>Velcade</b> among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.<span class="mw-ref" id="cite_ref-AHFS2019_1-0"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> This includes multiple myeloma in those who have and have not previously received treatment.<span class="mw-ref" id="cite_ref-EMA2019_2-0"><a href="#cite_note-EMA2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is generally used together with other medications.<span class="mw-ref" id="cite_ref-EMA2019_2-1"><a href="#cite_note-EMA2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is given by injection.<span class="mw-ref" id="cite_ref-AHFS2019_1-1"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>



<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Bortezomib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Bortezomib.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bortezomib.svg.png" data-file-width="512" data-file-height="357" data-file-type="drawing" height="153" width="220"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Bortezomib-based-on-PDB-2F16-Mercury-3D-balls.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bortezomib-based-on-PDB-2F16-Mercury-3D-balls.png" data-file-width="2000" data-file-height="1522" data-file-type="bitmap" height="167" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Velcade, Chemobort, Bortecad, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>PS-341</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/bortezomib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/bortezomib.html'" tppabs="https://www.drugs.com/monograph/bortezomib.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a607007.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a607007.html'" tppabs="https://medlineplus.gov/druginfo/meds/a607007.html" class="external text external">a607007</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bortezomib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bortezomib'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bortezomib" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bortezomib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bortezomib'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bortezomib" class="external text external">Bortezomib</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bortezomib&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bortezomib&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bortezomib&SearchType=BasicSearch" class="external text external">Bortezomib</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>D (Evidence of risk)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous,  IV</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XX32<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XX32  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XX32'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XX32" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>83%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver, CYP extensively involved</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>9 to 15 hours</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">[(1<i>R</i>)-3-methyl-1-({(2<i>S</i>)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=179324-69-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=179324-69-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=179324-69-7" class="external text external">179324-69-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/387447  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/387447'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/387447" class="external text external">387447</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391" class="external text external">6391</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00188'" tppabs="https://www.drugbank.ca/drugs/DB00188" class="external text external">DB00188</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.343402.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.343402.html'" tppabs="http://www.chemspider.com/Chemical-Structure.343402.html" class="external text external">343402</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=69G8BD63PP  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=69G8BD63PP'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=69G8BD63PP" class="external text external">69G8BD63PP</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL325041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL325041'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL325041" class="external text external">ChEMBL325041</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PDB ligand</th><td><div class="plainlist"><ul><li>BO2 (<span><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BO2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BO2'" tppabs="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BO2" class="external text external">PDBe</a></span>, <span><a href="javascript:if(confirm('http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BO2&polymericType=Any  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BO2&polymericType=Any'" tppabs="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BO2&polymericType=Any" class="external text external">RCSB<span>&nbsp;</span>PDB</a></span>)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID3040980  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID3040980'" tppabs="https://comptox.epa.gov/dashboard/DTXSID3040980" class="external text external">DTXSID3040980</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.125.601  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.125.601'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.125.601" class="external text external">100.125.601</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>19</sub><span>H</span><sub>25</sub><span>B</span><span>N</span><sub>4</sub><span>O</span><sub>4</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">384.24</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28C%28%3DO%29N%5BC%40H%5D%28B%28O%29O%29CC%28C%29C%29Cc1ccccc1%29c2nccnc2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28C%28%3DO%29N%5BC%40H%5D%28B%28O%29O%29CC%28C%29C%29Cc1ccccc1%29c2nccnc2'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28C%28%3DO%29N%5BC%40H%5D%28B%28O%29O%29CC%28C%29C%29Cc1ccccc1%29c2nccnc2" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C(N[C@H](C(=O)N[C@H](B(O)O)CC(C)C)Cc1ccccc1)c2nccnc2</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:GXJABQQUPOEUTA-RDJZCZTQSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459493462&page2=Bortezomib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459493462&page2=Bortezomib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459493462&page2=Bortezomib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include nausea, diarrhea, tiredness, low platelets, fever, numbness, low white blood cells, shortness of breath, rash and abdominal pain.<span class="mw-ref" id="cite_ref-AHFS2019_1-2"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Other severe side effects include low blood pressure, tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome.<span class="mw-ref" id="cite_ref-AHFS2019_1-3"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-EMA2019_2-2"><a href="#cite_note-EMA2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is in the class of medications known as proteasome inhibitor.<span class="mw-ref" id="cite_ref-AHFS2019_1-4"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It works by inhibiting proteasomes, cellular complexes that break down proteins.<span class="mw-ref" id="cite_ref-EMA2019_2-3"><a href="#cite_note-EMA2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Bortezomib was approved for medical use in the United States in 2003 and in Europe in 2004.<span class="mw-ref" id="cite_ref-AHFS2019_1-5"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-EMA2019_2-4"><a href="#cite_note-EMA2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.<span class="mw-ref" id="cite_ref-WHO21st_3-0"><a href="#cite_note-WHO21st-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> In the United States it costs US$1,360 per 3.5<span>&nbsp;</span>mg vial.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In the United Kingdom this amount costs the NHS £762 such that a course of treatment is about £12,261 as of 2014.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_use">Medical use</h2></summary>
    
<p>Two open-label trials established the efficacy of bortezomib (with or without <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a>) on days 1,4,8, and 11 of a 21-day cycle for a maximum of eight cycles in heavily pretreated people with relapsed/refractory multiple myeloma.<span class="mw-ref" id="cite_ref-Curran2009_6-0"><a href="#cite_note-Curran2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The phase III demonstrated the superiority of bortezomib over a high-dose dexamethasone regimen (e.g. median TTP 6.2 vs 3.5 months, and 1-year survival 80% vs 66%).<span class="mw-ref" id="cite_ref-Curran2009_6-1"><a href="#cite_note-Curran2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> New studies show that bortezomib may potentially help recover from vincristine treatment in treating acute lymphoblastic leukemia, when replacing vincristine in the process.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>Gastro-intestinal (GI) effects and asthenia are the most common adverse events.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> Bortezomib is associated with peripheral neuropathy in 30% of patients resulting in pain.  This can be worse in patients with pre-existing neuropathy. In addition, myelosuppression causing neutropenia and thrombocytopenia can also occur and be dose-limiting. However, these side effects are usually mild relative to bone marrow transplantation and other treatment options for patients with advanced disease. Bortezomib is associated with a high rate of shingles,<span class="mw-ref" id="cite_ref-pmid15953001_9-0"><a href="#cite_note-pmid15953001-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> although prophylactic <a href="Aciclovir.htm" tppabs="https://ptable.com/wiki/compounds/A/Acyclovir" title="Acyclovir" class="mw-redirect">acyclovir</a> can reduce the risk of this.<span class="mw-ref" id="cite_ref-pmid19406726_10-0"><a href="#cite_note-pmid19406726-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Ocular side effects such as chalazion or hordeolum (stye) may be more common in women and have led to discontinuation of treatment.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span>  Acute interstitial nephritis has also been reported.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Drug_interactions">Drug interactions</h2></summary>
    
<p>Polyphenols derived from green tea extract including <a href="Epigallocatechin_gallate.htm" tppabs="https://ptable.com/wiki/compounds/A/Epigallocatechin_gallate" title="Epigallocatechin gallate">epigallocatechin gallate</a> (EGCG), which were expected to have a synergistic effect, instead were found to reduce the effectiveness of bortezomib in cell culture experiments.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    
<div class="thumb tleft"><div class="thumbinner" style="width:202px"><img src="../I/m/2f16.png" tppabs="https://ptable.com/wiki/compounds/I/m/2f16.png" data-file-width="640" data-file-height="480" data-file-type="bitmap" height="150" width="200"><div class="thumbcaption" style="text-align: left">Bortezomib bound to the core particle in a yeast proteasome. The bortezomib molecule is in the center colored by atom type (boron = pink, carbon = cyan, nitrogen = blue, oxygen = red), surrounded by the local protein surface. The blue patch is  catalytic <a href="Threonine.htm" tppabs="https://ptable.com/wiki/compounds/A/Threonine" title="Threonine">threonine</a> residue whose activity is blocked by the presence of bortezomib.</div></div></div>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Structure">Structure</h3></summary>
    
<p>The drug is an N-protected dipeptide and can be written as Pyz-Phe-boroLeu, which stands for <a href="Pyrazinoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrazinoic_acid" title="Pyrazinoic acid">pyrazinoic acid</a>, <a href="Phenylalanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylalanine" title="Phenylalanine">phenylalanine</a> and <a href="Leucine.htm" tppabs="https://ptable.com/wiki/compounds/A/Leucine" title="Leucine">Leucine</a> with a boronic acid instead of a carboxylic acid.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism">Mechanism</h3></summary>
    
<p>The <a href="Boron.htm" tppabs="https://ptable.com/wiki/compounds/A/Boron" title="Boron">boron</a> atom in bortezomib binds the catalytic site of the 26S proteasome<span class="mw-ref" id="cite_ref-pmid17268529_14-0"><a href="#cite_note-pmid17268529-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> with high affinity and specificity. In normal cells, the proteasome regulates protein expression and function by degradation of ubiquitylated proteins, and also rids the cell of abnormal or misfolded proteins. Clinical and preclinical data support a role for the proteasome in maintaining the immortal phenotype of myeloma cells, and cell-culture and xenograft data support a similar function in solid tumor cancers. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent degradation of pro-apoptotic factors, thereby triggering programmed cell death in neoplastic cells. Recently, it was found that bortezomib caused a rapid and dramatic change in the levels of intracellular peptides that are produced by the proteasome.<span class="mw-ref" id="cite_ref-pmid23308178_15-0"><a href="#cite_note-pmid23308178-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Some intracellular peptides have been shown to be biologically active, and so the effect of bortezomib on the levels of intracellular peptides may contribute to the biological and/or side effects of the drug.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics_and_pharmacodynamics">Pharmacokinetics and pharmacodynamics</h3></summary>
    
<p>After subcutaneous administration, peak plasma levels are ~25-50 nM and this peak is sustained for 1-2 hrs. After intravenous injection, peak plasma levels are ~500 nM but only for ~5 minutes, after which the levels rapidly drop as the drug distributes to tissues (volume of distribution is ~500 L).<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> Both routes provide equal drug exposures and generally comparable therapeutic efficacy. Elimination half life is 9–15 hours and the drug is primarily cleared by hepatic metabolism.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>The pharmacodynamics of bortezomib are determined by quantifying proteasome inhibition in peripheral blood mononuclear cells taken from patients receiving the drug.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Bortezomib was originally made in 1995 at Myogenics. The drug (PS-341) was tested in a small Phase I clinical trial on patients with multiple myeloma. It was brought to further clinical trials by Millennium Pharmaceuticals in October 1999.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>In May 2003, seven years after the initial synthesis, bortezomib (marketed as Velcade by Millennium Pharmaceuticals Inc.) was approved in the United States by the U.S. Food and Drug Administration (FDA) for use in multiple myeloma, based on the results from the SUMMIT Phase II trial.<span class="mw-ref" id="cite_ref-pmid15199612_20-0"><a href="#cite_note-pmid15199612-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> In 2008, bortezomib was approved in the United States for initial treatment of patients with multiple myeloma.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-0"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Bortezomib was previously approved in 2005, for the treatment of patients with multiple myeloma who had received at least one prior therapy and in 2003, for the treatment of more refractory multiple myeloma.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-1"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>The 2008 approval was based on an international, multicenter, open label, active-control trial in previously untreated patients with symptomatic multiple myeloma.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-2"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Patients were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-3"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Patients received M (9<span>&nbsp;</span>mg/m2 ) plus prednisone (60<span>&nbsp;</span>mg/m2 ) daily for four days every 6 weeks or the same MP schedule with bortezomib, 1.3<span>&nbsp;</span>mg/m2 iv on days 1, 8, 11, 22, 25, 29, and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks for 5 cycles.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-4"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Time- to- progression (TTP) was the primary efficacy endpoint.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-5"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Overall survival (OS), progression-free survival (PFS), and response rate (RR) were secondary endpoints.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-6"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Eligible patients were age &gt; 65 years.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-7"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> A total of 682 patients were randomized: 338 to receive MP and 344 to the combination of bortezomib plus MP.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-8"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span>  Demographics and baseline disease characteristics were similar between the two groups.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-9"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>The trial was stopped following a pre-specified interim analysis showing a statistically significant improvement in TTP with the addition of bortezomib to MP (median 20.7 months) compared with MP (median 15 months) [HR: 0.54 (95% CI: 0.42, 0.70), p= 0.000002].<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-10"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span>  OS, PFS, and RR also were significantly superior for the bortezomib-MP combination.<span class="mw-ref" id="cite_ref-FDA_PR_2008_22-11"><a href="#cite_note-FDA_PR_2008-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>In August 2014, bortezomib was approved in the United States for the retreatment of adult patients with multiple myeloma<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-pmid26629279_24-0"><a href="#cite_note-pmid26629279-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> who had previously responded to Velcade therapy and relapsed at least six months following completion of prior treatment.<span class="mw-ref" id="cite_ref-pmid26629279_24-1"><a href="#cite_note-pmid26629279-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>In October 2014, bortezomib was approved in the United States for the treatment of treatment-naïve patients with mantle cell lymphoma (MCL).<span class="mw-ref" id="cite_ref-pmid26629279_24-2"><a href="#cite_note-pmid26629279-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Costs">Costs</h2></summary>
    
<p>In the UK, NICE initially recommended against Velcade in October 2006 due to its cost of about £18,000 per person, and because studies reviewed by NICE reported that it could only extend the life expectancy by an average of six months over standard treatment.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> However, the company later proposed a performance-linked cost reduction for multiple myeloma,<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> and this was accepted.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Ixazomib, a proteasome inhibitor that is given by mouth</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-AHFS2019-1"> <span id="mw-reference-text-cite_note-AHFS2019-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/bortezomib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/bortezomib.html'" tppabs="https://www.drugs.com/monograph/bortezomib.html" class="external text external">"Bortezomib Monograph for Professionals"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2019</span>.</cite></span></li><li id="cite_note-EMA2019-2"> <span id="mw-reference-text-cite_note-EMA2019-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/velcade  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/velcade'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/velcade" class="external text external">"Velcade"</a>. <i>European Medicines Agency</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2019</span>.</cite></span></li><li id="cite_note-WHO21st-3"> <span id="mw-reference-text-cite_note-WHO21st-3" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation journal cs1">World Health Organization (2019). "World Health Organization model list of essential medicines: 21st list 2019". World Health Organization (WHO). hdl:<a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a>.</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/price-guide/bortezomib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/price-guide/bortezomib'" tppabs="https://www.drugs.com/price-guide/bortezomib" class="external text external">"Bortezomib Prices, Coupons &amp; Patient Assistance Programs"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2019</span>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nice.org.uk/guidance/ta311/documents/multiple-myeloma-bortezomib-induction-therapy-fad-document2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nice.org.uk/guidance/ta311/documents/multiple-myeloma-bortezomib-induction-therapy-fad-document2'" tppabs="https://www.nice.org.uk/guidance/ta311/documents/multiple-myeloma-bortezomib-induction-therapy-fad-document2" class="external text external">"Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation"</a>. <i>NICE</i>. February 2014. p.<span>&nbsp;</span>2<span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2019</span>.</cite></span></li><li id="cite_note-Curran2009-6"> <span id="mw-reference-text-cite_note-Curran2009-6" class="mw-reference-text"><cite id="CITEREFCurranMcKeage2009" class="citation journal cs1">Curran M, McKeage K (2009). <a href="javascript:if(confirm('https://web.archive.org/web/20111008153521/http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111008153521/http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx'" tppabs="https://web.archive.org/web/20111008153521/http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx" class="external text external">"Bortezomib: A Review of its Use in Patients with Multiple Myeloma"</a>. <i>Drugs</i>. <b>69</b> (7): 859–888. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200969070-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200969070-00006'" tppabs="https://doi.org/10.2165%2F00003495-200969070-00006" class="external text external">10.2165/00003495-200969070-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19441872  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19441872'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19441872" class="external text external">19441872</a>. Archived from <a href="javascript:if(confirm('http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx'" tppabs="http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx" class="external text external">the original</a> on 2011-10-08<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-03-26</span></span>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text">Joshi, Jaitri, et al. “Switching to Bortezomib May Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia.” Journal of Pediatric Hematology/Oncology, vol. 41, no. 6, Aug. 2019, pp. 457–462., doi:10.1097/mph.0000000000001529.</span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><a href="javascript:if(confirm('http://www.velcade.com/full_prescrib_velcade.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.velcade.com/full_prescrib_velcade.pdf'" tppabs="http://www.velcade.com/full_prescrib_velcade.pdf" class="external text external">Highlights Of Prescribing Information</a> <a href="javascript:if(confirm('https://web.archive.org/web/20090219102450/http://www.velcade.com/full_prescrib_velcade.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090219102450/http://www.velcade.com/full_prescrib_velcade.pdf'" tppabs="https://web.archive.org/web/20090219102450/http://www.velcade.com/full_prescrib_velcade.pdf" class="external text external">Archived</a><span> February 19, 2009, at the </span>Wayback Machine</span></li><li id="cite_note-pmid15953001-9"> <span id="mw-reference-text-cite_note-pmid15953001-9" class="mw-reference-text"><cite id="CITEREFOakerveePopatCurry2005" class="citation journal cs1">Oakervee HE, Popat R, Curry N,  et al. (2005). "PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma". <i>Br J Haematol</i>. <b>129</b> (6): 755–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2141.2005.05519.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2141.2005.05519.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2141.2005.05519.x" class="external text external">10.1111/j.1365-2141.2005.05519.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15953001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15953001'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15953001" class="external text external">15953001</a>.</cite></span></li><li id="cite_note-pmid19406726-10"> <span id="mw-reference-text-cite_note-pmid19406726-10" class="mw-reference-text"><cite id="CITEREFPour_L.Adam_Z.Buresova_L.2009" class="citation journal cs1">Pour L.; Adam Z.; Buresova L.;  et al. (2009). "Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib". <i>Clinical Lymphoma &amp; Myeloma</i>. <b>9</b> (2): 151–3. doi:<a href="javascript:if(confirm('https://doi.org/10.3816%2FCLM.2009.n.036  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3816%2FCLM.2009.n.036'" tppabs="https://doi.org/10.3816%2FCLM.2009.n.036" class="external text external">10.3816/CLM.2009.n.036</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19406726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19406726'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19406726" class="external text external">19406726</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFDennisMaozHughesSanchorawala2019" class="citation journal cs1">Dennis, Michael; Maoz, Asaf; Hughes, David; Sanchorawala, Vaishali; Sloan, J. Mark; Sarosiek, Shayna (2019). <a href="javascript:if(confirm('https://doi.org/10.1002/ajh.25382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002/ajh.25382'" tppabs="https://doi.org/10.1002/ajh.25382" class="external text external">"Bortezomib ocular toxicities: Outcomes with ketotifen"</a>. <i>American Journal of Hematology</i>. <b>0</b> (3): E80–E82. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1002%2Fajh.25382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fajh.25382'" tppabs="https://doi.org/10.1002%2Fajh.25382" class="external text external">10.1002/ajh.25382</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1096-8652  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1096-8652'" tppabs="https://www.worldcat.org/issn/1096-8652" class="external text external">1096-8652</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30575098  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30575098'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30575098" class="external text external">30575098</a>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFCheungpasitpornLeungRajkumarCornell2015" class="citation journal cs1">Cheungpasitporn, Wisit; Leung, Nelson; Rajkumar, S. Vincent; Cornell, Lynn D.; Sethi, Sanjeev; Angioi, Andrea; Fervenza, Fernando C. (2015). <a href="javascript:if(confirm('https://doi.org/10.1093/ndt/gfv222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/ndt/gfv222'" tppabs="https://doi.org/10.1093/ndt/gfv222" class="external text external">"Bortezomib-induced acute interstitial nephritis"</a>. <i>Nephrol. Dial. Transplant</i>. <b>30</b> (7): 1225–1229. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fndt%2Fgfv222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fndt%2Fgfv222'" tppabs="https://doi.org/10.1093%2Fndt%2Fgfv222" class="external text external">10.1093/ndt/gfv222</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26109684  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26109684'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26109684" class="external text external">26109684</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFGoldenLamKardoshGaffney2009" class="citation journal cs1">Golden, EB; Lam, PY; Kardosh, A; Gaffney, KJ; Cadenas, E; Louie, SG; Petasis, NA; Chen, TC; Schönthal, AH (4 June 2009). <a href="javascript:if(confirm('https://doi.org/10.1182/blood-2008-07-171389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182/blood-2008-07-171389'" tppabs="https://doi.org/10.1182/blood-2008-07-171389" class="external text external">"Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors"</a>. <i>Blood</i>. <b>113</b> (23): 5927–37. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2008-07-171389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2008-07-171389'" tppabs="https://doi.org/10.1182%2Fblood-2008-07-171389" class="external text external">10.1182/blood-2008-07-171389</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19190249  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19190249'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19190249" class="external text external">19190249</a>.</cite></span></li><li id="cite_note-pmid17268529-14"> <span id="mw-reference-text-cite_note-pmid17268529-14" class="mw-reference-text"><cite id="CITEREFBonviniZorziBassoRosolen2007" class="citation journal cs1">Bonvini P, Zorzi E, Basso G, Rosolen A (2007). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.leu.2404528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.leu.2404528'" tppabs="https://doi.org/10.1038/sj.leu.2404528" class="external text external">"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma"</a>. <i>Leukemia</i>. <b>21</b> (4): 838–42. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.leu.2404528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.leu.2404528'" tppabs="https://doi.org/10.1038%2Fsj.leu.2404528" class="external text external">10.1038/sj.leu.2404528</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17268529  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17268529'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17268529" class="external text external">17268529</a>.</cite></span></li><li id="cite_note-pmid23308178-15"> <span id="mw-reference-text-cite_note-pmid23308178-15" class="mw-reference-text"><cite id="CITEREFGelmanSironiBerezniukDasgupta2013" class="citation journal cs1">Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785" class="external text external">"Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib"</a>. <i>PLOS ONE</i>. <b>8</b> (1): e53263. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2013PLoSO...853263G  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2013PLoSO...853263G'" tppabs="https://ui.adsabs.harvard.edu/abs/2013PLoSO...853263G" class="external text external">2013PLoSO...853263G</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pone.0053263  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pone.0053263'" tppabs="https://doi.org/10.1371%2Fjournal.pone.0053263" class="external text external">10.1371/journal.pone.0053263</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538785" class="external text external">3538785</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23308178  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23308178'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23308178" class="external text external">23308178</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFReeceSullivanLonialMohrbacher2011" class="citation journal cs1">Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A (2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913" class="external text external">"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma"</a>. <i>Cancer Chemother. Pharmacol</i>. <b>67</b> (1): 57–67. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00280-010-1283-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00280-010-1283-3'" tppabs="https://doi.org/10.1007%2Fs00280-010-1283-3" class="external text external">10.1007/s00280-010-1283-3</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951913" class="external text external">3951913</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20306195  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20306195'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20306195" class="external text external">20306195</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFVoorheesDeesO'NeilOrlowski2003" class="citation journal cs1">Voorhees PM, Dees EC, O'Neil B, Orlowski RZ (2003). "The proteasome as a target for cancer therapy". <i>Clin Cancer Res</i>. <b>9</b> (17): 6316–25. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14695130  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14695130'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14695130" class="external text external">14695130</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFMoreauPylypenkoGrosickiKaramanesht2011" class="citation journal cs1">Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011). "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study". <i>The Lancet Oncology</i>. <b>12</b> (5): 431–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs1470-2045%2811%2970081-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs1470-2045%2811%2970081-x'" tppabs="https://doi.org/10.1016%2Fs1470-2045%2811%2970081-x" class="external text external">10.1016/s1470-2045(11)70081-x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21507715  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21507715'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21507715" class="external text external">21507715</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFLarkin1999" class="citation journal cs1">Larkin, Marilynn (November 1999). "(In)famous trials brought to life". <i>The Lancet</i>. <b>354</b> (9193): 1915. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0140-6736%2805%2976886-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0140-6736%2805%2976886-0'" tppabs="https://doi.org/10.1016%2Fs0140-6736%2805%2976886-0" class="external text external">10.1016/s0140-6736(05)76886-0</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0140-6736  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0140-6736'" tppabs="https://www.worldcat.org/issn/0140-6736" class="external text external">0140-6736</a>.</cite></span></li><li id="cite_note-pmid15199612-20"> <span id="mw-reference-text-cite_note-pmid15199612-20" class="mw-reference-text"><cite id="CITEREFAdamsKauffman2004" class="citation journal cs1">Adams J, Kauffman M (2004). "Development of the Proteasome Inhibitor Velcade (Bortezomib)". <i>Cancer Invest</i>. <b>22</b> (2): 304–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1081%2FCNV-120030218  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1081%2FCNV-120030218'" tppabs="https://doi.org/10.1081%2FCNV-120030218" class="external text external">10.1081/CNV-120030218</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15199612  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15199612'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15199612" class="external text external">15199612</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm" class="external text external">"Drug Approval Package: Velcade (Bortezomib) NDA #021602"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 13 May 2003. <a href="javascript:if(confirm('https://web.archive.org/web/20191205163541/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191205163541/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm'" tppabs="https://web.archive.org/web/20191205163541/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm" class="external text external">Archived</a> from the original on 5 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 December</span> 2019</span>.</cite><figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_PR_2008-22"> <span id="mw-reference-text-cite_note-FDA_PR_2008-22" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20111201193227/https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111201193227/https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm'" tppabs="https://web.archive.org/web/20111201193227/https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm" class="external text external">"Velcade (bortezomib) is Approved for Initial Treatment of Patients with Multiple Myeloma"</a> (Press release). U.S. Food and Drug Administration (FDA). June 23, 2008. Archived from <a href="javascript:if(confirm('https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm'" tppabs="https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm" class="external text external">the original</a> on 1 December 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">5 December</span> 2019</span>.</cite><figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20181101191919/http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight=  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20181101191919/http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight='" tppabs="https://web.archive.org/web/20181101191919/http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight=" class="external text external">"Millennium: The Takeda Oncology Company"</a>. <i>.millennium.com</i>. 2014-08-08. Archived from <a href="javascript:if(confirm('http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight=  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight='" tppabs="http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1957192&highlight=" class="external text external">the original</a> on 2018-11-01.</cite></span></li><li id="cite_note-pmid26629279-24"> <span id="mw-reference-text-cite_note-pmid26629279-24" class="mw-reference-text"><cite id="CITEREFRaedler2015" class="citation journal cs1">Raedler L (March 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054" class="external text external">"Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma"</a>. <i>Am Health Drug Benefits</i>. <b>8</b> (Spec Feature): 135–40. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665054" class="external text external">4665054</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26629279  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26629279'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26629279" class="external text external">26629279</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://news.bbc.co.uk/1/hi/health/6069386.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bbc.co.uk/1/hi/health/6069386.stm'" tppabs="http://news.bbc.co.uk/1/hi/health/6069386.stm" class="external text external">"NHS watchdog rejects cancer drug"</a>. BBC News UK. 2006-10-20<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-08-14</span></span>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090419091212/http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090419091212/http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf'" tppabs="https://web.archive.org/web/20090419091212/http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf" class="external text external">"Summary of VELCADE Response Scheme"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf'" tppabs="http://www.nice.org.uk/nicemedia/pdf/MyelomaDofHSummaryResponderScheme.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2009-04-19<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-08-14</span></span>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20110710204841/http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110710204841/http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html'" tppabs="https://web.archive.org/web/20110710204841/http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html" class="external text external">"More Velcade-Style Risk-Sharing In The UK?"</a>. Euro Pharma Today. 2009-01-21. Archived from <a href="javascript:if(confirm('http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html'" tppabs="http://www.europharmatoday.com/2009/01/more-velcadestyle-risksharing-in-the-uk.html" class="external text external">the original</a> on 2011-07-10<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-08-14</span></span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/bortezomib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/bortezomib'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/bortezomib" class="external text external">"Bortezomib"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Intracellular_chemotherapeutic_agents_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Intracellular_chemotherapeutic_agents_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Intracellular chemotherapeutic agents<span>&nbsp;</span>/ antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">SPs/MIs<br>(M phase)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Block microtubule assembly</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Vinca alkaloids</i> (<a href="Vinblastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vinblastine" title="Vinblastine">Vinblastine</a><sup>#</sup></li>
<li><a href="Vincristine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vincristine" title="Vincristine">Vincristine</a><sup>#</sup></li>
<li><a href="Vindesine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vindesine" title="Vindesine">Vindesine</a></li>
<li>Vinflunine<sup>§</sup></li>
<li><a href="Vinorelbine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vinorelbine" title="Vinorelbine">Vinorelbine</a><sup>#</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Block microtubule disassembly</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Taxanes</i> (Cabazitaxel</li>
<li><a href="Docetaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Docetaxel" title="Docetaxel">Docetaxel</a><sup>#</sup></li>
<li>Larotaxel</li>
<li>Ortataxel<sup>†</sup></li>
<li><a href="Paclitaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Paclitaxel" title="Paclitaxel">Paclitaxel</a><sup>#</sup></li>
<li>Tesetaxel)</li>
<li><i>Epothilones</i> (Ixabepilone)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">DNA replication<br>inhibitor</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">DNA precursors/<br>antimetabolites<br>(S phase)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Folic acid</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Dihydrofolate reductase inhibitor</i> (<a href="Aminopterin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminopterin" title="Aminopterin">Aminopterin</a></li>
<li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a><sup>#</sup></li>
<li><a href="Pemetrexed.htm" tppabs="https://ptable.com/wiki/compounds/A/Pemetrexed" title="Pemetrexed">Pemetrexed</a></li>
<li>Pralatrexate)</li>
<li><i>Thymidylate synthase inhibitor</i> (<a href="Pemetrexed.htm" tppabs="https://ptable.com/wiki/compounds/A/Pemetrexed" title="Pemetrexed">Pemetrexed</a></li>
<li><a href="Raltitrexed.htm" tppabs="https://ptable.com/wiki/compounds/A/Raltitrexed" title="Raltitrexed">Raltitrexed</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Purine</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Adenosine deaminase inhibitor</i> (<a href="Pentostatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentostatin" title="Pentostatin">Pentostatin</a>)</li></ul>

<ul><li><i>Halogenated/ribonucleotide reductase inhibitors</i> (<a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Cladribine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Cladribine'" tppabs="https://ptable.com/wiki/compounds/A/Cladribine" title="Cladribine">Cladribine</a></li>
<li><a href="Clofarabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clofarabine" title="Clofarabine">Clofarabine</a></li>
<li><a href="Fludarabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludarabine" title="Fludarabine">Fludarabine</a>)</li>
<li><a href="Nelarabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nelarabine" title="Nelarabine">Nelarabine</a></li></ul>

<ul><li><i>Thiopurine</i> (<a href="Mercaptopurine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mercaptopurine" title="Mercaptopurine">Mercaptopurine</a><sup>#</sup></li>
<li><a href="Tioguanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tioguanine" title="Tioguanine">Tioguanine</a><sup>#</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pyrimidine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Thymidylate synthase inhibitor</i> (<a href="Capecitabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Capecitabine" title="Capecitabine">Capecitabine</a><sup>#</sup></li>
<li><a href="Carmofur.htm" tppabs="https://ptable.com/wiki/compounds/A/Carmofur" title="Carmofur">Carmofur</a></li>
<li>Doxifluridine</li>
<li><a href="Floxuridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Floxuridine" title="Floxuridine">Floxuridine</a></li>
<li><a href="Fluorouracil.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorouracil" title="Fluorouracil">Fluorouracil</a><sup>#</sup></li>
<li><a href="Tegafur.htm" tppabs="https://ptable.com/wiki/compounds/A/Tegafur" title="Tegafur">Tegafur</a> (+gimeracil/oteracil))</li></ul>

<ul><li><i>DNA polymerase inhibitor</i> (<a href="Cytarabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cytarabine" title="Cytarabine">Cytarabine</a><sup>#</sup>)</li></ul>

<ul><li><i>Ribonucleotide reductase inhibitor</i> (<a href="Gemcitabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Gemcitabine" title="Gemcitabine">Gemcitabine</a><sup>#</sup>)</li></ul>

<ul><li><i>Hypomethylating agent</i> (<a href="Azacitidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azacitidine" title="Azacitidine">Azacitidine</a></li>
<li>Decitabine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Deoxyribonucleotide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Ribonucleotide reductase inhibitor</i> (<a href="Hydroxycarbamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxycarbamide" title="Hydroxycarbamide">Hydroxycarbamide</a><sup>#</sup>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Topoisomerase inhibitors<br>(S phase)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">I</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Camptotheca</i> (Belotecan</li>
<li><a href="Camptothecin.htm" tppabs="https://ptable.com/wiki/compounds/A/Camptothecin" title="Camptothecin">Camptothecin</a></li>
<li><span class="new">Cositecan</span><sup>†</sup></li>
<li>Exatecan</li>
<li><span class="new">Gimatecan</span></li>
<li><a href="Irinotecan.htm" tppabs="https://ptable.com/wiki/compounds/A/Irinotecan" title="Irinotecan">Irinotecan</a><sup>#</sup></li>
<li>Lurtotecan<sup>‡</sup></li>
<li>Rubitecan<sup>‡</sup></li>
<li><span class="new">Silatecan</span><sup>§</sup></li>
<li>Topotecan)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">II</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Podophyllum</i> (<a href="Etoposide.htm" tppabs="https://ptable.com/wiki/compounds/A/Etoposide" title="Etoposide">Etoposide</a><sup>#</sup></li>
<li><a href="Teniposide.htm" tppabs="https://ptable.com/wiki/compounds/A/Teniposide" title="Teniposide">Teniposide</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">II+Intercalation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Anthracyclines</i> (Aclarubicin</li>
<li>Amrubicin<sup>†</sup></li>
<li><a href="Daunorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Daunorubicin" title="Daunorubicin">Daunorubicin</a><sup>#</sup></li>
<li><a href="Doxorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxorubicin" title="Doxorubicin">Doxorubicin</a><sup>#</sup></li>
<li><a href="Epirubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Epirubicin" title="Epirubicin">Epirubicin</a></li>
<li><a href="Idarubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Idarubicin" title="Idarubicin">Idarubicin</a></li>
<li><a href="Pirarubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Pirarubicin" title="Pirarubicin">Pirarubicin</a></li>
<li><a href="Valrubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Valrubicin" title="Valrubicin">Valrubicin</a></li>
<li>Zorubicin)</li>
<li><i><a href="Anthraquinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Anthraquinone" title="Anthraquinone">Anthracenediones</a></i> (<a href="Mitoxantrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li>Pixantrone)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Crosslinking of DNA<br>(CCNS)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Alkylating</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nitrogen mustards:</i> Bendamustine<sup>#</sup></li>
<li>Chlormethine</li>
<li><a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a><sup>#</sup> (<a href="Ifosfamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Ifosfamide" title="Ifosfamide">Ifosfamide</a><sup>#</sup></li>
<li>Trofosfamide)</li>
<li><a href="Chlorambucil.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorambucil" title="Chlorambucil">Chlorambucil</a><sup>#</sup> (<a href="Melphalan.htm" tppabs="https://ptable.com/wiki/compounds/A/Melphalan" title="Melphalan">Melphalan</a></li>
<li><a href="Prednimustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednimustine" title="Prednimustine">Prednimustine</a>)</li>
<li><a href="Uramustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Uramustine" title="Uramustine">Uramustine</a></li></ul>

<ul><li><i>Nitrosoureas:</i> <a href="Carmustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carmustine" title="Carmustine">Carmustine</a></li>
<li><a href="Fotemustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fotemustine" title="Fotemustine">Fotemustine</a></li>
<li><a href="Lomustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lomustine" title="Lomustine">Lomustine</a> (<a href="Semustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Semustine" title="Semustine">Semustine</a>)</li>
<li>Nimustine</li>
<li>Ranimustine</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Streptozotocin  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Streptozotocin'" tppabs="https://ptable.com/wiki/compounds/A/Streptozotocin" title="Streptozotocin">Streptozocin</a></li></ul>

<ul><li><i>Alkyl sulfonates:</i> <a href="Busulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Busulfan" title="Busulfan">Busulfan</a> (Mannosulfan</li>
<li><a href="Treosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Treosulfan" title="Treosulfan">Treosulfan</a>)</li></ul>

<ul><li><i><a href="Aziridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Aziridine" title="Aziridine">Aziridines</a>:</i> Carboquone</li>
<li>Thiotepa</li>
<li><a href="Triaziquone.htm" tppabs="https://ptable.com/wiki/compounds/A/Triaziquone" title="Triaziquone">Triaziquone</a></li>
<li><a href="Triethylenemelamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Triethylenemelamine" title="Triethylenemelamine">Triethylenemelamine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Platinum-based</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Carboplatin  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Carboplatin'" tppabs="https://ptable.com/wiki/compounds/A/Carboplatin" title="Carboplatin">Carboplatin</a><sup>#</sup></li>
<li><a href="Cisplatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cisplatin" title="Cisplatin">Cisplatin</a><sup>#</sup></li>
<li>Dicycloplatin</li>
<li>Nedaplatin</li>
<li><a href="Oxaliplatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaliplatin" title="Oxaliplatin">Oxaliplatin</a><sup>#</sup></li>
<li>Satraplatin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Nonclassical</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Altretamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Altretamine" title="Altretamine">Altretamine</a></li>
<li><i><a href="Hydrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrazine" title="Hydrazine">Hydrazines</a></i> (<a href="Procarbazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Procarbazine" title="Procarbazine">Procarbazine</a><sup>#</sup>)</li>
<li><a href="Mitobronitol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitobronitol" title="Mitobronitol">Mitobronitol</a></li>
<li><a href="Pipobroman.htm" tppabs="https://ptable.com/wiki/compounds/A/Pipobroman" title="Pipobroman">Pipobroman</a></li>
<li><i>Triazenes</i> (<a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Dacarbazine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Dacarbazine'" tppabs="https://ptable.com/wiki/compounds/A/Dacarbazine" title="Dacarbazine">Dacarbazine</a><sup>#</sup></li>
<li><a href="Temozolomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Temozolomide" title="Temozolomide">Temozolomide</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intercalation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Streptomyces (<a href="Actinomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Actinomycin" title="Actinomycin" class="mw-redirect">Actinomycin</a><sup>#</sup></li>
<li><a href="Bleomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bleomycin" title="Bleomycin">Bleomycin</a><sup>#</sup></li>
<li>Mitomycins</li>
<li><a href="Plicamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Plicamycin" title="Plicamycin">Plicamycin</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Photosensitizers/PDT</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aminolevulinic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminolevulinic_acid" title="Aminolevulinic acid">Aminolevulinic acid</a><span>&nbsp;</span>/ <a href="Methyl_aminolevulinate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_aminolevulinate" title="Methyl aminolevulinate">Methyl aminolevulinate</a></li>
<li>Efaproxiral</li>
<li>Padeliporfin</li>
<li><i><a href="Porphyrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Porphyrin" title="Porphyrin">Porphyrin derivatives</a></i> (<a href="Porfimer_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Porfimer_sodium" title="Porfimer sodium">Porfimer sodium</a></li>
<li>Talaporfin</li>
<li>Temoporfin</li>
<li><a href="Verteporfin.htm" tppabs="https://ptable.com/wiki/compounds/A/Verteporfin" title="Verteporfin">Verteporfin</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Enzyme inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FI</i> (Tipifarnib<sup>§</sup>)</li>
<li><i>CDK inhibitors</i> (Abemaciclib</li>
<li>Alvocidib<sup>†</sup></li>
<li>Palbociclib</li>
<li>Ribociclib</li>
<li>Seliciclib<sup>†</sup>)</li>
<li><i>PrI</i>
<ul><li><a href="Bortezomib.htm" tppabs="https://ptable.com/wiki/compounds/A/Bortezomib" title="Bortezomib">Bortezomib</a></li>
<li>Carfilzomib</li>
<li>Ixazomib</li></ul></li>
<li><i>PhI</i> (<a href="Anagrelide.htm" tppabs="https://ptable.com/wiki/compounds/A/Anagrelide" title="Anagrelide">Anagrelide</a>)</li>
<li><i>IMPDI</i> (Tiazofurin<sup>§</sup>)</li>
<li><i>LI</i> (<a href="Masoprocol.htm" tppabs="https://ptable.com/wiki/compounds/A/Masoprocol" title="Masoprocol">Masoprocol</a>)</li>
<li><i>PARP inhibitor</i> (Niraparib</li>
<li>Olaparib</li>
<li>Rucaparib)</li>
<li><i>HDAC</i> (Belinostat</li>
<li>Panobinostat</li>
<li>Romidepsin</li>
<li><a href="Vorinostat.htm" tppabs="https://ptable.com/wiki/compounds/A/Vorinostat" title="Vorinostat">Vorinostat</a>)</li>
<li><i>PIKI</i> (Alpelisib</li>
<li>Idelalisib)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>ERA</i> (Atrasentan)</li>
<li><i>Retinoid X receptor</i> (<a href="Bexarotene.htm" tppabs="https://ptable.com/wiki/compounds/A/Bexarotene" title="Bexarotene">Bexarotene</a>)</li>
<li><i>Sex steroid</i> (<a href="Testolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testolactone" title="Testolactone">Testolactone</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other/ungrouped</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amsacrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amsacrine" title="Amsacrine">Amsacrine</a></li>
<li><a href="Arsenic_trioxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Arsenic_trioxide" title="Arsenic trioxide">Arsenic trioxide</a></li>
<li><i><a href="Asparagine.htm" tppabs="https://ptable.com/wiki/compounds/A/Asparagine" title="Asparagine">Asparagine depleters</a></i> (<a href="Asparaginase.htm" tppabs="https://ptable.com/wiki/compounds/A/Asparaginase" title="Asparaginase">Asparaginase</a><sup>#</sup>/<a href="Pegaspargase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegaspargase" title="Pegaspargase">Pegaspargase</a>)</li>
<li><a href="Celecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Celecoxib" title="Celecoxib">Celecoxib</a></li>
<li><a href="Demecolcine.htm" tppabs="https://ptable.com/wiki/compounds/A/Demecolcine" title="Demecolcine">Demecolcine</a></li>
<li>Elesclomol<sup>§</sup></li>
<li>Elsamitrucin</li>
<li>Eribulin</li>
<li>Estramustine phosphate</li>
<li><a href="Etoglucid.htm" tppabs="https://ptable.com/wiki/compounds/A/Etoglucid" title="Etoglucid">Etoglucid</a></li>
<li><a href="Lonidamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lonidamine" title="Lonidamine">Lonidamine</a></li>
<li>Lucanthone</li>
<li>Mitoguazone</li>
<li><a href="Mitotane.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitotane" title="Mitotane">Mitotane</a></li>
<li>Oblimersen<sup>†</sup></li>
<li>Omacetaxine mepesuccinate</li>
<li>Trabectedin</li>
<li><i>Retinoids</i> (<a href="Alitretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Alitretinoin" title="Alitretinoin">Alitretinoin</a></li>
<li><a href="Tretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tretinoin" title="Tretinoin">Tretinoin</a><sup>#</sup>)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>












<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-11" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Bortezomib&oldid=972342406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Bortezomib&oldid=972342406'" tppabs="https://en.wikipedia.org/wiki/?title=Bortezomib&oldid=972342406">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>